For instance, some clinical trials of anti‐PD‐L1 immunotherapy have revealed that NSCLC patients with EGFR overexpression and mutation exhibit poorer treatment outcomes compared to those with WT EGFR, which is mainly modulated by the TME. Here, EGFR is linked to non-small cell lung carcinoma.